News

Effective immediately, Alliance BMP will account for financial results from its 50% stake in Guangzhou Pharmaceuticals (GP), the third largest pharmaceutical wholesaler in China. The accretive transaction is

The company has received final approval following the expiration of Roche’s patent on December 28, 2007, and plans to launch its product shortly. Kytril (granisetron hydrochloride) tablets, 1mg

The drug is indicated to treat breathing difficulty in patients with chronic obstructive pulmonary disease (COPD). Shipment of the product will begin immediately. The company claims that the

The claims in the suit include breach of confidentiality agreements, conversion of Kinetic Concepts (KCI) technology, theft of trade secrets and conspiracy. KCI is seeking damages and injunctive

Exactech announced the exercise of its option and execution of a merger agreement to acquire Altiva in December, 2007 based on a valuation of $25 million. Exactech’s final

Sular is a calcium channel blocking agent for the treatment of high blood pressure. The new Sular formulation utilizes SkyePharma’s patented Geomatrix technology, which provides a lower dose

Under the agreement, Keata has agreed to employ substantially all of the workforce of approximately 175 people at the 85,000 sq. ft. facility, including 38 acres of land,

Under the terms of the agreement, Sepracor will be responsible for filing the US NDA and seeking marketing approval from the FDA. Sepracor anticipates that the NDA will

Glumetza (metformin hydrochloride extended release tablets) is indicated alone or in combination with a sulfonylurea or insulin as an adjunct to diet and exercise to improve glycemic control